drugset / Trial / NCT02913716
A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects
NaSingle-groupOpen-labelOther
Summary
This study assesses the mass balance recovery, pharmacokinetics, metabolite profile and metabolite identification of defactinib.
Timeline
- Start
- 2015-08
- Primary completion
- 2015-09
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Defactinib | Small molecule | 400 mg | Oral |
Indications
No indication recorded.